Share on StockTwits

ImmunoCellular Therapeutics (NASDAQ:IMUC) VP Anthony Gringeri purchased 11,000 shares of ImmunoCellular Therapeutics stock on the open market in a transaction that occurred on Thursday, August 21st. The stock was purchased at an average price of $0.91 per share, for a total transaction of $10,010.00. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

Several analysts have recently commented on the stock. Analysts at Roth Capital upgraded shares of ImmunoCellular Therapeutics from a “neutral” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $3.00 price target on the stock, up previously from $2.00. Analysts at Maxim Group cut their price target on shares of ImmunoCellular Therapeutics from $12.00 to $4.00 in a research note on Monday, June 2nd. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. ImmunoCellular Therapeutics currently has an average rating of “Buy” and an average price target of $3.31.

ImmunoCellular Therapeutics (NASDAQ:IMUC) traded up 2.12% on Friday, hitting $0.9191. 259,377 shares of the company’s stock traded hands. ImmunoCellular Therapeutics has a 1-year low of $0.65 and a 1-year high of $4.00. The stock has a 50-day moving average of $0.97 and a 200-day moving average of $1.16. The company’s market cap is $55.8 million.

ImmunoCellular Therapeutics (NASDAQ:IMUC) last announced its earnings results on Monday, August 11th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.06) by $0.02. Analysts expect that ImmunoCellular Therapeutics will post $-0.22 EPS for the current fiscal year.

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors.

Receive News & Ratings for ImmunoCellular Therapeutics Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoCellular Therapeutics Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.